Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical ...

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will ...

In a phase 3 trial, the daily GLP-1 pill has shown "meaningful weight loss" and similar side effects to injectable GLP-1 ...

Oikos Fusion offers a nutrient-dense dairy drink designed to support muscle mass and digestive health during weight loss ...

GLP-1 medications have an impressive history of weight loss, but there are options to consider. For example, one study on the oral medication Qsymia found people lost up to 11% of their body ...

The Hunting Wives' actress Chrissy Metz gets candid in a new cover story for PEOPLE on her thoughts about using weight loss ...